(MENAFN- Gulf Times) Sidra Medicine, a member of Qatar Foundation, has appointed Prof Christof von Kalle as its new chief research officer (CRO).
In his capacity as CRO, Prof Kalle will oversee all aspects of research conducted at the institution. Working with a team of international and local experts, his goal will be to align the activities of the clinical and research branches towards breakthroughs in patient care.
Under Prof Kalle's leadership, the research team at Sidra Medicine 'will become a beacon of excellence in healthcare research, new therapeutic developments and world-class education with the ultimate goal of making significant contributions to Qatar's healthcare and education system, according to a press statement.
Peter Morris, CEO of Sidra Medicine, said: 'The research conducted at Sidra Medicine is one of the key foundations that will advance precision medicine and personalised care for women, children and young people in Qatar and beyond. We are pleased to welcome Prof Kalle to Sidra Medicine and are certain that his extensive experience will contribute to the acceleration of our research goals.
As a physician scientist with a clinical background in cancer research, Prof Kalle is an internationally renowned scientific leader in stem cell research and the treatment of rare genetic diseases. He has published over 150 high-impact publications and is an elected member of the European Academy of Cancer Sciences.
Prof Kalle joined Sidra Medicine from the National Centre for Tumour Diseases (NCT) where he held the position of director. At the NCT, Prof Kalle facilitated translational and clinical research by working with colleagues to build internationally renowned research groups for stem?cell research, applied functional genomics, lymphoma research, molecular diagnostics and gene therapy. He is the co-founder of two biotech companies, Lifecodexx and GeneWerk.
Prof. Kalle has been the recipient of several prestigious awards over the years, including the Pioneer Series Award for Human Gene Therapy in 2011, the Eva Luise Köhler Award for Rare Diseases in 2005, and the Langen Research Award from Paul-Ehrlich-Institute in Langen, Germany in 2004.
'With a state-of-the-art facility and an ambitious vision to become one of the top academic medical centres in the world, Sidra Medicine is well-equipped to foster impactful scientific and clinical research both in Qatar and beyond, said Prof Kalle. 'Through our collaboration with Qatar Biobank and its Qatar Genome Programme as well as other healthcare organisations in the country, Sidra Medicine will provide unique and valuable research results for the benefit of women and children.
MENAFN2705201800670000ID1096914546
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.